IL106135A - Nicotinic acid esters and pharmaceutical compositions containing them - Google Patents

Nicotinic acid esters and pharmaceutical compositions containing them

Info

Publication number
IL106135A
IL106135A IL10613593A IL10613593A IL106135A IL 106135 A IL106135 A IL 106135A IL 10613593 A IL10613593 A IL 10613593A IL 10613593 A IL10613593 A IL 10613593A IL 106135 A IL106135 A IL 106135A
Authority
IL
Israel
Prior art keywords
group
formula
compound
compounds
general formula
Prior art date
Application number
IL10613593A
Other languages
English (en)
Other versions
IL106135A0 (en
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of IL106135A0 publication Critical patent/IL106135A0/xx
Publication of IL106135A publication Critical patent/IL106135A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL10613593A 1992-06-25 1993-06-24 Nicotinic acid esters and pharmaceutical compositions containing them IL106135A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201956A SE9201956D0 (sv) 1992-06-25 1992-06-25 Novel nicotinicacid esters

Publications (2)

Publication Number Publication Date
IL106135A0 IL106135A0 (en) 1993-10-20
IL106135A true IL106135A (en) 1999-01-26

Family

ID=20386602

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10613593A IL106135A (en) 1992-06-25 1993-06-24 Nicotinic acid esters and pharmaceutical compositions containing them

Country Status (27)

Country Link
US (1) US5658910A (cs)
EP (2) EP1120410B1 (cs)
JP (1) JP3306827B2 (cs)
KR (1) KR100302216B1 (cs)
CN (1) CN1085981C (cs)
AT (2) ATE209634T1 (cs)
AU (1) AU681346B2 (cs)
BG (1) BG62000B1 (cs)
CA (1) CA2139112C (cs)
CZ (1) CZ281975B6 (cs)
DE (2) DE69333655D1 (cs)
DK (1) DK0673368T3 (cs)
EE (1) EE03122B1 (cs)
ES (1) ES2169044T3 (cs)
FI (1) FI107151B (cs)
HU (2) HU220613B1 (cs)
IL (1) IL106135A (cs)
NO (1) NO302945B1 (cs)
NZ (1) NZ253823A (cs)
PH (1) PH31417A (cs)
PT (1) PT673368E (cs)
RO (1) RO115725B1 (cs)
RU (1) RU2127732C1 (cs)
SE (1) SE9201956D0 (cs)
SK (1) SK279393B6 (cs)
WO (1) WO1994000434A1 (cs)
ZA (1) ZA934596B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
SK286641B6 (sk) * 1999-05-04 2009-03-05 Schering Corporation Piperazínové deriváty užitočné ako CCR5 antagonisty, farmaceutické prípravky s ich obsahom a ich použitie
SE9904673D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
ES2319876T3 (es) * 2001-05-18 2009-05-14 Astrazeneca Ab Derivados de 4 (fenil-piperazinil-metil) benzamida y su uso para el tratamiento de la ansiedad o trastornos gastrointestinales.
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
KR102325422B1 (ko) * 2018-05-09 2021-11-11 주식회사 엘지화학 엔테로펩티다아제 억제 활성을 나타내는 신규 화합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457931A (en) * 1982-09-27 1984-07-03 Selvi & C. S.P.A. Piperazine derivatives with anticholinergic and/or antihistaminic activity
EP0264883A3 (en) * 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Substituted pyridine derivatives
SE8701375D0 (sv) * 1987-04-02 1987-04-02 Leo Ab Novel pyridyl- and pyrimidyl derivatives
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
JP2664238B2 (ja) * 1989-03-01 1997-10-15 日清製粉株式会社 ニコチン酸またはそのエステル誘導体
US4956368A (en) * 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
EP0441226A1 (en) * 1990-01-29 1991-08-14 J. URIACH & CIA. S.A. (cyanomethyl)pyridines useful as PAF antagonists
IE911774A1 (en) * 1990-06-11 1991-12-18 Akzo Nv Pyridinylpiperazine derivatives
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
SE9202265D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel- pyridyl and pyrimidylpiperazine derivatives

Also Published As

Publication number Publication date
RU2127732C1 (ru) 1999-03-20
JP3306827B2 (ja) 2002-07-24
CZ281975B6 (cs) 1997-04-16
US5658910A (en) 1997-08-19
SK279393B6 (sk) 1998-11-04
FI946085L (fi) 1994-12-23
BG99289A (bg) 1995-09-29
HU220613B1 (hu) 2002-03-28
HU210875A9 (en) 1995-08-28
WO1994000434A1 (en) 1994-01-06
EP0673368B1 (en) 2001-11-28
ATE209634T1 (de) 2001-12-15
RU94046310A (ru) 1996-10-27
FI946085A0 (fi) 1994-12-23
NZ253823A (en) 1996-01-26
SE9201956D0 (sv) 1992-06-25
EP1120410B1 (en) 2004-10-06
CA2139112C (en) 2006-03-21
KR100302216B1 (ko) 2001-11-22
NO945022D0 (no) 1994-12-23
CA2139112A1 (en) 1994-01-06
EE03122B1 (et) 1998-10-15
DE69333655D1 (de) 2004-11-11
PH31417A (en) 1998-10-29
CN1086811A (zh) 1994-05-18
HUT71406A (en) 1995-11-28
RO115725B1 (ro) 2000-05-30
KR950702186A (ko) 1995-06-19
DK0673368T3 (da) 2002-03-18
BG62000B1 (bg) 1998-12-30
AU4519393A (en) 1994-01-24
SK158594A3 (en) 1995-07-11
ZA934596B (en) 1994-02-14
DE69331234T2 (de) 2002-08-08
DE69331234D1 (de) 2002-01-10
AU681346B2 (en) 1997-08-28
PT673368E (pt) 2002-05-31
NO945022L (no) 1995-02-13
NO302945B1 (no) 1998-05-11
EP0673368A1 (en) 1995-09-27
CZ327494A3 (en) 1995-09-13
IL106135A0 (en) 1993-10-20
HU9403786D0 (en) 1995-02-28
EP1120410A1 (en) 2001-08-01
CN1085981C (zh) 2002-06-05
ATE278671T1 (de) 2004-10-15
JPH07508517A (ja) 1995-09-21
ES2169044T3 (es) 2002-07-01
FI107151B (fi) 2001-06-15

Similar Documents

Publication Publication Date Title
JP2873025B2 (ja) １‐［モノ―もしくはビス（トリフルオロメチル）‐２‐ピリジニル］ピペラジンを含有する薬剤組成物
JPH05502682A (ja) ピペラジン誘導体
EP0361271B1 (en) Pyridyl- and pyrimidyl derivatives
JP3068875B2 (ja) アミン誘導体、その製造方法、心臓脈管疾患および症状を治療するための医薬
AU681346B2 (en) Novel nicotinic acid esters
FI88300C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara diazinylpiperidinderivat av cykliska amider och imider
US6326371B1 (en) Pyrudyl and pyrimidylpiperazine derivatives
GB2162843A (en) Piperazine derivatives
CA2053980A1 (en) 4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinyl-alkyl substituted lactams
NO179409B (no) Psykoaktive 4-[4-eller 6-(trifluormetyl-2-pyridinyl)Å-1-piperazinyl-alkylsubstituerte laktamer og anvendelse derav

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HP Change in proprietorship
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees